CABENUVA 200 MG / ML — DIN 02497247
CABENUVA · VIIV HEALTHCARE ULC · wholesale supply in Canada
Health Canada status: MARKETED
What is CABENUVA?
CABENUVA 200 MG / ML contains CABENUVA. It is listed in the Health Canada Drug Product Database under DIN 02497247, held by VIIV HEALTHCARE ULC. Health Canada currently lists it as marketed, status dated 21-Sep-2020. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is CABENUVA used for?
Treatment of HIV-1 in virologically stable/suppressed (HIV-1 RNA <50 copies/mL) patients ≥12 years and ≥35 kg. VOCABRIA used as oral lead-in or bridging; CABENUVA as complete long-acting regimen.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 200 MG / ML |
|---|---|
| Pack configuration (monograph) | VOCABRIA: 30 mg tablets. CABENUVA: 2 mL and 3 mL dosing kits containing cabotegravir and rilpivirine suspensions. |
| Storage | CABENUVA: Store at 2°C to 8°C. Do not freeze. VOCABRIA: Store at 15°C to 30°C. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02497247 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2497247 |
| Brand name | CABENUVA |
| Generic / active ingredient | CABENUVA |
| Market authorization holder | VIIV HEALTHCARE ULC |
| Health Canada schedule | PRESCRIPTION |
| Current status | MARKETED |
| Status date | 21-Sep-2020 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Oral lead-in (30mg/25mg) for ~28 days (optional). Initiation: 600mg/900mg IM. Continuation: 400mg/600mg IM monthly or 600mg/900mg IM every 2 months. Gluteal IM injection only.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to cabotegravir or rilpivirine. Co-administration with strong inducers of UGT1A1/UGT1A9 (e.g., carbamazepine, rifampin, phenytoin), rifabutin, systemic dexamethasone, St John’s wort.
Warnings and precautions
Risk of virologic failure/resistance if doses missed. Depressive disorders, hepatotoxicity, post-injection reactions, and hypersensitivity reactions reported. Long-acting properties persist after stop.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.